Posted by Michael Wonder on 11 Nov 2021
Tremfya (guselkumab) approved for reimbursement in Ireland for active psoriatic arthritis
11 November 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that Tremfya (guselkumab), a first-in-class treatment for adult patients with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior disease-modifying anti-rheumatic drug therapy has been granted reimbursement in Ireland.
It is already approved for the treatment of patients with moderate to severe plaque psoriasis.
